Autolus Therapeutics (AUTL) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• Autolus Therapeutics is set to announce its Q2 2025 earnings on August 12, expecting a loss of ($0.23) per share and revenue of $12.92 million.
• The stock price has seen a 1.4% decline recently, opening at $2.35, with a market cap of $624.36 million and PE ratio of -2.76.
• Analysts have set a buy rating for the stock, with Needham & Company assigning a price target of $10.00, while the average target price stands at $9.32.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Tuesday, August 12th. Analysts expect Autolus Therapeutics to post earnings of ($0.23) per share and revenue of $12.92 million for the quarter.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The business had revenue of $8.98 million during the quarter, compared to analyst estimates of $1.59 million. On average, analysts expect Autolus Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Autolus Therapeutics Stock Down 1.4%

NASDAQ:AUTL opened at $2.35 on Tuesday. The business's 50-day simple moving average is $2.28 and its two-hundred day simple moving average is $1.89. The stock has a market cap of $624.36 million, a PE ratio of -2.76 and a beta of 1.90. Autolus Therapeutics has a 52 week low of $1.11 and a 52 week high of $5.00.

Analysts Set New Price Targets

Separately, Needham & Company LLC reissued a "buy" rating and set a $10.00 price target on shares of Autolus Therapeutics in a report on Monday, July 21st. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $9.32.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Autolus Therapeutics stock. Invesco Ltd. increased its holdings in Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) by 53.3% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 32,738 shares of the company's stock after buying an additional 11,381 shares during the period. Invesco Ltd.'s holdings in Autolus Therapeutics were worth $51,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.